Key facts, as of
As of November 6, 2026, Zoetis Inc. (ZTS) trades at $79.40, down 33.6% over the past year. Its 52-week range runs from $68.77 to $132.49; the price is 40.1% below that high. It is 68.1% below its all-time high of $249.27, reached in December 2021. Over the 10 years to the end of October 2026, with dividends reinvested, it returned +83.3%, against +316.3% for the S&P 500 (SPY). It sits 14.2% below its 200-day average of $92.50. Its 30-day volatility is 49.1% annualized, which we rate high risk. It has a trailing P/E of 13.5 and a dividend yield of 2.67%.
Cite: Portfolio Terminal, "Zoetis Inc. (ZTS) stock analysis", 2026-11-06. https://portfolio-terminal.com/analyse/zts
Where it trades today
trading 17% of the way up its 52-week range
How the price has moved
How far it is from its record
Zoetis Inc. (ZTS) is 68.1% below its all-time high of $249.27, reached in December 2021. Over the 10 years to the end of October 2026, with dividends reinvested, it returned +83.3%, against +316.3% for the S&P 500 (SPY).
The read, from its own figures
What its numbers say
- ZTS closes above its 50-day average ($75.69) while the 50-day is still under the 200-day ($92.50): a rebound inside a longer decline, not yet an uptrend.
- At $79.40, ZTS is 40.1% below its 1-year high of $132.49, set on February 12, 2026, and 15.5% above its 1-year low of $68.77 (October 2, 2026).
- Over the past month ZTS rose 8.6%, from $73.08 to $79.40.
- ZTS trades at 13.5x its last twelve months of earnings and 12.4x the next twelve months' estimate, so analysts expect earnings 8.9% higher.
- ZTS's 30-day volatility, 49.1% a year, works out to a typical daily move of about 3.1%.
- Yahoo Finance puts its beta at 0.68: over five years of monthly returns, ZTS moved about 0.68% for each 1% move of the S&P 500.
What would change the read
- The rebound holds while it closes above the 50-day average, $75.69 (−4.7%); it becomes an uptrend when the 50-day climbs 22.2% to cross the 200-day at $92.50.
- A close above $132.49 (+66.9%) would be a new 1-year high; below $68.77 (−13.4%), a new 1-year low.
How it is computed
- Prices are Yahoo Finance's daily candles for ZTS, the same ones the chart below draws; the P/E, forward P/E and beta are Yahoo Finance quote fields.
- The averages are simple means of the last 50 and 200 closes; the 1-year high and low are the highest high and lowest low of the last 252 sessions; the 30-day volatility is the standard deviation of the past month's daily returns, annualized with the square root of 252.
- Every sentence here is written by code from those figures, refreshed daily; nobody edits it for ZTS by hand. It describes what the price and the multiples have done, not what they will do, and it is not advice.
Sources
What Zoetis Inc. does
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care…
Employees
14,500
Industry
Drug Manufacturers - Specialty & Generic
Headquarters
Parsippany, United States
What analysts expect
ZTS carries a buy consensus from 13 analysts, with an average price target of $89.69 versus $79.40 today (+13.0%). Targets are estimates and can move quickly after earnings.
Consensus aggregated by Yahoo Finance. Targets are estimates, not forecasts.
How the business is doing
ZTS generated $9.49B in trailing revenue (-1.3% year over year), with a 26.4% net margin, and $2.05B of free cash flow, against $7.72B of net debt.
The numbers, year by year
| Fiscal year | Revenue | Gross profit | Operating income | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|---|
| 2025 | $9.47B | $6.80B | $3.60B | $2.67B | $6.03 | $2.28B |
| 2024 | $9.26B | $6.54B | $3.39B | $2.49B | $5.47 | $2.30B |
| 2023 | $8.54B | $5.98B | $3.07B | $2.34B | $5.08 | $1.62B |
| 2022 | $8.08B | $5.63B | $2.93B | $2.11B | $4.51 | $1.33B |
When it reports next
Estimates aggregated by Yahoo Finance. Dates move and estimates change until the report lands.
Which ETFs hold it
ZTS is in 18 of the 54 ETFs we track. It weighs most in XLV: 0.51% of the fund, holding #39 of 62.
Famous investors who hold it
ZTS is in the latest 13F of 1 of the 15 famous investors we follow. Renaissance Technologies (Founded by Jim Simons) holds the most of it: 0.14% of the portfolio, position #157 of 2,931, as of Q2 2026.
What the chart is saying
Back above its 50-day average, still under the long-term trend.
recovering- Price is 4.9% above its 50-day average and 14.2% below its 200-day.
- RSI at 51 is neither stretched nor washed out.
- The nearest ceiling is $82.54 (+4.0%), the nearest floor $77.96 (-1.8%).
A description of the chart, not advice. Indicators describe what the price has done; none of them knows what it does next.
Questions people ask about it
How is ZTS valued right now?
Zoetis Inc. trades at 13.5 times its last twelve months of earnings and 12.4 times the next twelve months' estimate (Yahoo Finance, November 6, 2026). On the chart: back above its 50-day average, still under the long-term trend. Price is 4.9% above its 50-day average and 14.2% below its 200-day.
What is the risk level of ZTS?
Based on 30-day volatility of 49.1%, ZTS has HIGH risk. Its beta of 0.68 means it has swung less than the S&P 500 over the last five years.
Does ZTS pay dividends?
Yes, Zoetis Inc. has a dividend yield of 2.67%.
How far is ZTS from its all-time high?
Zoetis Inc. is 68.1% below its all-time high of $249.27, reached in December 2021. Over the 10 years to the end of October 2026, with dividends reinvested, it returned +83.3%, against +316.3% for the S&P 500 (SPY).
Which ETFs hold ZTS?
18 of the 54 popular ETFs we track hold Zoetis Inc.. The largest weights: XLV (0.51%), VO (0.26%), RSP (0.22%), VIG (0.13%) and VYM (0.12%). Measured on each issuer's full holdings file, dated September 30 to October 18, 2026.
How much of VOO is ZTS?
0.04%, as of September 30, 2026: ZTS is holding #308 of 505 in Vanguard's file for VOO. $1,000 in VOO puts about $0.44 in Zoetis Inc..
Which famous investors own ZTS?
Renaissance Technologies (0.14% of Founded by Jim Simons's 13F), according to their latest Form 13F filings with the SEC (Q2 2026). A 13F lists US long positions 45 days after the quarter ends, so it can be out of date.
What is the analyst price target for ZTS?
The average analyst price target for Zoetis Inc. (ZTS) is $89.69 based on 13 analyst estimates, about 13.0% above the current price of $79.40. The published range runs from $73.00 to $115.00.
How much revenue does ZTS generate?
Zoetis Inc. reported $9.49B in trailing twelve-month revenue. Revenue growth is running at -1.3% year over year. Net margin sits at 26.4%. Figures are aggregated from company filings by Yahoo Finance and refresh on an hourly cadence.
Compare ZTS with anything
Five years side by side: what $10,000 became, how far each fell, whether they move together.
